Posted inBiotechnology
Dual radioligand therapy targets neuroendocrine bone metastases in pilot study
When cancer spreads to bone from a neuroendocrine tumor, patients face a double burden: the tumor itself keeps growing, and…
Posted inBiotechnology
VMA21 loss disrupts autophagy and vesicle trafficking in X-linked myopathy
In a significant advance for understanding a rare and devastating muscle disease, researchers at Washington University School of Medicine in…
Posted inBiotechnology
X-ray fluorescence mapping and quantification of metal(loid)s in animal samples
A new comprehensive review published in Environmental Chemistry Letters surveys more than three decades of X-ray fluorescence research in animal…
Posted inBiotechnology
Band gap, refractive index, and reflectivity of InSb and PdSe₂ nanostructures vary with dimensionality
In a finding that could reshape how researchers design the next generation of optoelectronic devices, physicists at the University of…
Posted inBiotechnology
Manganese Doping Boosts ZnO Oxygen Defects for Tandem CO2 Conversion to Olefins
The drive to transform carbon dioxide from a climate liability into a chemical feedstock has taken a significant step forward,…
Posted inBiotechnology
How reactive polymers and crumb rubber work together in asphalt compared with SBS
Every year, billions of tires reach the end of their service life, and while a portion of that rubber is…
Posted inBiotechnology
Bagasse lignin enables multifunctional anisotropic non-isocyanate polyurethane composites with graphite
In a development that could reshape how flexible electronics and wearable sensors are manufactured, researchers at Queensland University of Technology…
Posted inBiotechnology
Ensemble learning and social networks improve credit access for constrained borrowers
Financial constraints have long been one of the most stubborn obstacles in corporate life. When a firm cannot tap external…
Posted inBiotechnology
Beeline flies into phase 3 as oral lupus drug soars past placebo
A phase 2 trial of Beeline Medicines’ afimetoran has hit its primary endpoint, positioning the biotech to swarm into pivotal…
Posted inBiotechnology
Evommune gives up hope for MRGPRX2 antagonist to treat itch after latest phase 2 fail
Evommune’s MRGPRX2 antagonist has flunked another phase 2 trial, wiping out the biotech’s last hopes of developing the therapy for…